This site is intended for U.S. healthcare professionals.
Menu
Close
About
Burden of IPD
Dosing
Dosing
Administration and implementation
Efficacy & Safety
Efficacy
Safety Profile
Immunogenicity
Support & Order
Videos
Materials
Order Prevnar 13®
Adherence
Resources
Events
In infants and young children, Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) is administered as a 4-dose series at 2, 4, 6 and 12 to 15 months of age.1*†‡
*The first dose may be given as early as 6 weeks of age.1
†The recommended dosing interval for the first, second and third doses is 4 to 8 weeks.1
‡The fourth dose should be administered at approximately 12 to 15 months of age and at least 2 months after the third dose.1
Model used for illustrative purposes only.
Helping to protect babies from invasive pneumococcal disease and acute otitis media1
PREVNAR includes both PREVNAR® (Pneumococcal 7-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]) and PREVNAR 13®*
* In the US, PCV7 was available from 2000 to 2010 and PCV13 has been available since 2010.
Offer resources that may help improve adherence to the CDC-recommended vaccine schedule
To stock Prevnar 13®, call 1-800-666-7248 or click here
Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.
Please see full Prescribing Information for Prevnar 13®.
Limitations of Use and Effectiveness
Limitations of Use and Effectiveness
Please see full Prescribing Information.
OK. We'll need you to sign in before we can determine if you are aligned with a sales representative.
If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.
Would you like to sign in now?